Featured Research

from universities, journals, and other organizations

Researchers Add New Drug Prophylactic Option Against Flu

Date:
January 29, 2004
Source:
Infectious Diseases Society Of America
Summary:
Didn't get your flu shot this season? A study published in the February 1 issue of The Journal of Infectious Diseases supports the efficacy of an adjunct to influenza vaccination.

Didn't get your flu shot this season? A study published in the February 1 issue of The Journal of Infectious Diseases supports the efficacy of an adjunct to influenza vaccination.

Researchers examined the common influenza season scenario of a household in which a family member is infected with influenza virus. They found that when the family member with influenza was treated with the antiviral drug oseltamivir, post-exposure oseltamivir prophylaxis of all other family members significantly reduced the frequency of virus transmission and illness in the household. Because households are important sites of influenza virus transmission, these results have implications for the management of influenza outbreaks in the community.

The prospective, open-label, randomized study was conducted in multiple centers in Europe and North America by Frederick G. Hayden, MD, of the University of Virginia and colleagues. They studied a total of 277 households with a suspected influenza introduction during the 2000-2001 season. These households had 298 ill index cases, 62% of whom were shown to be influenza-infected, and 812 contacts aged 1 year or older. In all households, the ill index member received a five-day course of oseltamivir treatment. In one-half of these households, the contacts received post-exposure prophylaxis with once daily oseltamivir for 10 days; in the other half, the household contacts received treatment only if they developed symptoms of illness. The researchers found that post-exposure prophylaxis combined with treatment of the ill household member was more effective in preventing subsequent influenza illness in contacts than treating the ill family member only. For all enrolled households, the protective efficacy of the post-exposure prophylaxis strategy was 63%, and prophylaxis reduced the number of individual contacts with laboratory-confirmed influenza illness by 73%.

Among other notable findings, the authors reported that oseltamivir was generally well tolerated in children and adults, although associated with some nausea and vomiting, and provided protection against illnesses caused by both influenza A and influenza B viruses. Oseltamivir use was not associated with transmission of drug-resistant virus, which had been a problem with some other antiviral drugs, the M2 protein inhibitors amantadine and rimantadine, when used for treatment and prophylaxis of influenza. However, early occurrence of illness in this study indicated that the treatment must be initiated quickly for optimal protection.

Dr. Hayden and colleagues noted that although oseltamivir post-exposure prophylaxis for influenza is not a substitute for vaccination, it may be valuable in certain situations because it affords immediate protection. They added that such situations include if vaccines are not available, in conjunction with vaccination late in the influenza season, before vaccine has induced an immune response, or if there is no immune response to the vaccine.

###

Founded in 1904, The Journal of Infectious Diseases is the premier publication in the Western Hemisphere for original research on the pathogenesis, diagnosis, and treatment of infectious diseases; on the microbes that cause them; and on disorders of host immune mechanisms. Articles in JID include research results from microbiology, immunology, epidemiology, and related disciplines. JID is published under the auspices of the Infectious Diseases Society of America (IDSA), based in Alexandria, Va., a professional society representing more than 7,500 physicians and scientists who specialize in infectious diseases.


Story Source:

The above story is based on materials provided by Infectious Diseases Society Of America. Note: Materials may be edited for content and length.


Cite This Page:

Infectious Diseases Society Of America. "Researchers Add New Drug Prophylactic Option Against Flu." ScienceDaily. ScienceDaily, 29 January 2004. <www.sciencedaily.com/releases/2004/01/040128074706.htm>.
Infectious Diseases Society Of America. (2004, January 29). Researchers Add New Drug Prophylactic Option Against Flu. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2004/01/040128074706.htm
Infectious Diseases Society Of America. "Researchers Add New Drug Prophylactic Option Against Flu." ScienceDaily. www.sciencedaily.com/releases/2004/01/040128074706.htm (accessed October 2, 2014).

Share This



More Health & Medicine News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pregnancy Spacing Could Have Big Impact On Autism Risks

Pregnancy Spacing Could Have Big Impact On Autism Risks

Newsy (Oct. 1, 2014) A new study says children born less than one year and more than five years after a sibling can have an increased risk for autism. Video provided by Newsy
Powered by NewsLook.com
Ebola Patient Told Hospital He Was from Liberia

Ebola Patient Told Hospital He Was from Liberia

AP (Oct. 1, 2014) The first Ebola patient diagnosed in the U.S. initially went to a Dallas emergency room last week but was sent home, despite telling a nurse that he had been in disease-ravaged West Africa, the hospital acknowledged Wednesday. (Oct. 1) Video provided by AP
Powered by NewsLook.com
Robotic Hair Restoration

Robotic Hair Restoration

Ivanhoe (Oct. 1, 2014) A new robotic procedure is changing the way we transplant hair. The ARTAS robot leaves no linear scarring and provides more natural results. Video provided by Ivanhoe
Powered by NewsLook.com
Insertable Cardiac Monitor

Insertable Cardiac Monitor

Ivanhoe (Oct. 1, 2014) A heart monitor the size of a paperclip that can save your life. The “Reveal Linq” allows a doctor to monitor patients with A-Fib on a continuous basis for up to 3 years! Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins